Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
PASADENA, Calif., April 24, 2018 -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-based cancer products using its proprietary technology, today announced it has received a BioLabs Golden Ticket from Paris-based biopharmaceutical company, Sanofi, to fund Meditope’s lab space. The work will be conducted at BioLabs in San Diego, part of a national network of premium co-working facilities designed to help science-based startups go further faster on limited capital investment.
This award marks the start of a research collaboration between Sanofi and Meditope, under which Meditope will conduct preclinical evaluation programs utilizing the bioconjugation technology SnAP (Site-specific novel Antibody Platform) it has developed over the past five years.
"This is a milestone for Meditope,” said Stephanie Hsieh, CEO of the Pasadena-based biotech company. “Our Sanofi relationship, with support from BioLabs, will allow us to explore novel, disease-specific applications of our proprietary SnAP technology to further prove its flexibility, simplicity and power to create new therapeutic approaches.”
As a Gold sponsor, Sanofi is helping to fund Meditope’s residence in BioLabs’ fully equipped, world-class scientific facility through the Golden Ticket program. This investment supports membership in BioLabs and the cost of one year of bench space in BioLabs’ shared lab, including all of BioLabs’ shared infrastructure, programming and services. Potential areas for further scientific evaluation of Meditope’s bioconjugation technology SnAP may include diabetes, cardiovascular, immunology and oncology.
“At BioLabs, one of our goals in establishing our innovation ecosystem is to ensure creative exchange happens formally and informally between our startups and sponsors — the Golden Ticket helps us toward that goal,” added Susie Harborth, co-founder, BioLabs San Diego, and COO, BioLabs. “We’re pleased to facilitate potential medical science breakthroughs.”
About Meditope Biosciences
Meditope Biosciences is a biotechnology company developing novel antibody-based cancer products using its SnAP technology (Site-specific novel Antibody Platform). Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, SnAP has the potential of turning any antibody into a proprietary, site-specific "LEGO-like" system that can attach and detach nearly anything to an antibody. Meditope's SnAP technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products. Visit www.meditope.com.
About BioLabs
A membership-based network of shared laboratory facilities located in key cities with proven biotech innovation clusters, BioLabs offers beautifully designed coworking environments that pair fully equipped and supported lab, office, and event spaces with relevant programming and unparalleled access to capital and industry partners. These fertile, supportive ecosystems allow young companies to shift their focus from startup operations to experimentation and innovation so they can reach their scientific potential quickly and achieve business success. Companies can start with a single lab bench and scale up as they grow. The expanding BioLabs network now comprises sites in Boston and Cambridge, Massachusetts; Durham, North Carolina; San Diego and San Francisco, California; New York City, and Princeton, New Jersey.
Media Contact:
Meditope Biosciences
PondelWilkinson Inc.
George Medici/Roger Pondel
310-279-5980
[email protected]; [email protected]
BioLabs
Caroline Grossman
781-771-5579
[email protected]
